Concepts (233)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Inflammatory Bowel Diseases | 8 | 2024 | 575 | 1.540 |
Why?
|
| Colorectal Neoplasms | 8 | 2024 | 981 | 1.410 |
Why?
|
| Adenocarcinoma | 10 | 2024 | 1194 | 1.330 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2022 | 111 | 1.030 |
Why?
|
| Endoscopic Mucosal Resection | 2 | 2022 | 27 | 0.910 |
Why?
|
| Lymphocytosis | 1 | 2022 | 12 | 0.850 |
Why?
|
| Gastritis | 1 | 2022 | 36 | 0.820 |
Why?
|
| Pathologists | 1 | 2021 | 27 | 0.740 |
Why?
|
| Lifting | 1 | 2020 | 12 | 0.730 |
Why?
|
| Smooth Muscle Tumor | 1 | 2020 | 5 | 0.710 |
Why?
|
| Barrett Esophagus | 1 | 2021 | 93 | 0.710 |
Why?
|
| Observer Variation | 1 | 2021 | 610 | 0.660 |
Why?
|
| Carcinogenesis | 3 | 2019 | 211 | 0.650 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2018 | 24 | 0.610 |
Why?
|
| Atrial Septum | 1 | 2017 | 9 | 0.590 |
Why?
|
| Lipomatosis | 1 | 2017 | 9 | 0.580 |
Why?
|
| Hamartoma | 1 | 2017 | 34 | 0.570 |
Why?
|
| Stomach Neoplasms | 4 | 2021 | 281 | 0.570 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2016 | 19 | 0.540 |
Why?
|
| Immunohistochemistry | 8 | 2024 | 1796 | 0.420 |
Why?
|
| Appendiceal Neoplasms | 2 | 2024 | 31 | 0.410 |
Why?
|
| Aged | 20 | 2024 | 19078 | 0.410 |
Why?
|
| Male | 26 | 2024 | 42254 | 0.390 |
Why?
|
| Liver | 4 | 2022 | 1205 | 0.380 |
Why?
|
| Peritoneal Neoplasms | 2 | 2024 | 184 | 0.380 |
Why?
|
| Humans | 38 | 2024 | 89073 | 0.360 |
Why?
|
| Middle Aged | 22 | 2024 | 25865 | 0.350 |
Why?
|
| Female | 24 | 2024 | 46014 | 0.340 |
Why?
|
| Adult | 17 | 2024 | 26508 | 0.340 |
Why?
|
| Esophageal Neoplasms | 3 | 2020 | 332 | 0.310 |
Why?
|
| Collagen | 3 | 2022 | 293 | 0.260 |
Why?
|
| Colitis | 2 | 2019 | 244 | 0.240 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2024 | 33 | 0.240 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2024 | 24 | 0.230 |
Why?
|
| Colonoscopy | 2 | 2024 | 279 | 0.230 |
Why?
|
| Siderosis | 1 | 2023 | 2 | 0.230 |
Why?
|
| Tumor Microenvironment | 2 | 2024 | 459 | 0.230 |
Why?
|
| Iron Overload | 1 | 2023 | 6 | 0.230 |
Why?
|
| Diet, Western | 2 | 2023 | 38 | 0.220 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 967 | 0.220 |
Why?
|
| Hepatitis | 1 | 2023 | 34 | 0.220 |
Why?
|
| Colorectal Surgery | 1 | 2023 | 22 | 0.220 |
Why?
|
| Colonic Polyps | 1 | 2024 | 132 | 0.220 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2023 | 48 | 0.210 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2022 | 11 | 0.210 |
Why?
|
| Precancerous Conditions | 1 | 2024 | 200 | 0.210 |
Why?
|
| Gastrointestinal Diseases | 1 | 2024 | 151 | 0.210 |
Why?
|
| Plasmacytoma | 1 | 2022 | 34 | 0.210 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2022 | 39 | 0.210 |
Why?
|
| Gastrointestinal Tract | 2 | 2022 | 191 | 0.210 |
Why?
|
| Cytomegalovirus Infections | 1 | 2023 | 146 | 0.210 |
Why?
|
| Aberrant Crypt Foci | 1 | 2022 | 7 | 0.200 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 91 | 0.200 |
Why?
|
| Goblet Cells | 1 | 2022 | 20 | 0.200 |
Why?
|
| Atrophy | 1 | 2022 | 119 | 0.200 |
Why?
|
| Adenomatoid Tumor | 1 | 2021 | 1 | 0.200 |
Why?
|
| Multiple Endocrine Neoplasia | 1 | 2021 | 7 | 0.200 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2021 | 23 | 0.200 |
Why?
|
| Aged, 80 and over | 7 | 2020 | 6777 | 0.200 |
Why?
|
| Esophageal Stenosis | 1 | 2021 | 26 | 0.200 |
Why?
|
| Appendix | 1 | 2021 | 31 | 0.190 |
Why?
|
| Liver Cirrhosis | 2 | 2021 | 254 | 0.190 |
Why?
|
| Portal Vein | 1 | 2021 | 120 | 0.180 |
Why?
|
| Intestinal Mucosa | 2 | 2024 | 805 | 0.180 |
Why?
|
| Mutation | 2 | 2024 | 4132 | 0.180 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2020 | 19 | 0.180 |
Why?
|
| Injections | 1 | 2020 | 116 | 0.180 |
Why?
|
| Surgical Stomas | 1 | 2020 | 22 | 0.180 |
Why?
|
| Buschke-Lowenstein Tumor | 1 | 2019 | 1 | 0.180 |
Why?
|
| Deglutition Disorders | 1 | 2021 | 119 | 0.180 |
Why?
|
| Hyperthermia, Induced | 1 | 2020 | 73 | 0.170 |
Why?
|
| Mentors | 1 | 2021 | 85 | 0.170 |
Why?
|
| Glutamate-Ammonia Ligase | 1 | 2019 | 12 | 0.170 |
Why?
|
| Fibrosis | 1 | 2021 | 234 | 0.170 |
Why?
|
| Cholangiocarcinoma | 1 | 2020 | 76 | 0.170 |
Why?
|
| Carcinoma in Situ | 1 | 2019 | 53 | 0.170 |
Why?
|
| Bile Duct Neoplasms | 1 | 2020 | 90 | 0.170 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2019 | 16 | 0.170 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2019 | 41 | 0.160 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2019 | 55 | 0.160 |
Why?
|
| Hyperplasia | 3 | 2024 | 152 | 0.160 |
Why?
|
| Glucuronosyltransferase | 1 | 2020 | 186 | 0.160 |
Why?
|
| Colitis, Lymphocytic | 1 | 2018 | 4 | 0.160 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 195 | 0.160 |
Why?
|
| Colectomy | 1 | 2019 | 172 | 0.160 |
Why?
|
| Multiple Myeloma | 1 | 2022 | 330 | 0.160 |
Why?
|
| Antidiarrheals | 1 | 2018 | 14 | 0.150 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 164 | 0.150 |
Why?
|
| Influenza, Human | 1 | 2021 | 337 | 0.150 |
Why?
|
| Anus Neoplasms | 1 | 2018 | 36 | 0.150 |
Why?
|
| Gene Amplification | 1 | 2018 | 134 | 0.150 |
Why?
|
| DNA Mutational Analysis | 1 | 2019 | 529 | 0.150 |
Why?
|
| Cetuximab | 1 | 2018 | 117 | 0.150 |
Why?
|
| Hypertrophy | 1 | 2017 | 67 | 0.150 |
Why?
|
| Mesalamine | 1 | 2018 | 88 | 0.150 |
Why?
|
| Biomarkers, Tumor | 3 | 2024 | 1543 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1363 | 0.140 |
Why?
|
| Camptothecin | 1 | 2018 | 193 | 0.140 |
Why?
|
| Steroids | 1 | 2018 | 174 | 0.140 |
Why?
|
| Endoscopy | 1 | 2020 | 348 | 0.140 |
Why?
|
| Fatal Outcome | 1 | 2017 | 299 | 0.140 |
Why?
|
| Neoplasm Metastasis | 1 | 2021 | 1108 | 0.140 |
Why?
|
| Fatty Liver, Alcoholic | 1 | 2016 | 6 | 0.140 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2019 | 447 | 0.140 |
Why?
|
| Hepatitis, Alcoholic | 1 | 2016 | 16 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 412 | 0.140 |
Why?
|
| Renin | 1 | 2016 | 67 | 0.140 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2016 | 21 | 0.140 |
Why?
|
| Defecation | 1 | 2016 | 23 | 0.140 |
Why?
|
| Rectal Diseases | 1 | 2016 | 24 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 2552 | 0.130 |
Why?
|
| Renin-Angiotensin System | 1 | 2016 | 81 | 0.130 |
Why?
|
| Choristoma | 1 | 2016 | 68 | 0.130 |
Why?
|
| Liver Transplantation | 1 | 2023 | 1177 | 0.130 |
Why?
|
| Stomach | 1 | 2016 | 111 | 0.130 |
Why?
|
| Disease Progression | 1 | 2020 | 1488 | 0.130 |
Why?
|
| Prognosis | 2 | 2020 | 3773 | 0.130 |
Why?
|
| Rectum | 1 | 2016 | 148 | 0.120 |
Why?
|
| Diarrhea | 1 | 2016 | 182 | 0.120 |
Why?
|
| Pandemics | 1 | 2021 | 771 | 0.120 |
Why?
|
| Papillomavirus Infections | 1 | 2018 | 261 | 0.120 |
Why?
|
| Young Adult | 3 | 2024 | 6289 | 0.120 |
Why?
|
| Colonic Neoplasms | 1 | 2019 | 573 | 0.120 |
Why?
|
| Adolescent | 3 | 2024 | 9237 | 0.120 |
Why?
|
| Child | 2 | 2024 | 7149 | 0.110 |
Why?
|
| Precision Medicine | 1 | 2017 | 410 | 0.110 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2016 | 173 | 0.110 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2019 | 504 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2019 | 1096 | 0.100 |
Why?
|
| Comorbidity | 1 | 2016 | 948 | 0.100 |
Why?
|
| Genomics | 1 | 2017 | 761 | 0.100 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2016 | 390 | 0.100 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 1591 | 0.100 |
Why?
|
| Biopsy | 3 | 2021 | 1182 | 0.090 |
Why?
|
| Anastomosis, Surgical | 2 | 2023 | 273 | 0.090 |
Why?
|
| Retrospective Studies | 5 | 2023 | 9003 | 0.090 |
Why?
|
| Neoplasm Grading | 2 | 2024 | 372 | 0.090 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 754 | 0.080 |
Why?
|
| Treatment Outcome | 5 | 2020 | 8203 | 0.080 |
Why?
|
| Postoperative Complications | 1 | 2019 | 2275 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 2 | 2023 | 1088 | 0.080 |
Why?
|
| Leucovorin | 2 | 2020 | 224 | 0.080 |
Why?
|
| Fluorouracil | 2 | 2020 | 561 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 285 | 0.070 |
Why?
|
| Colon | 2 | 2021 | 509 | 0.070 |
Why?
|
| Mice | 4 | 2023 | 11742 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2020 | 1855 | 0.060 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2024 | 8 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2023 | 2362 | 0.060 |
Why?
|
| Intestinal Neoplasms | 1 | 2024 | 64 | 0.060 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2024 | 103 | 0.060 |
Why?
|
| Transferrins | 1 | 2023 | 3 | 0.060 |
Why?
|
| Ferritins | 1 | 2023 | 29 | 0.060 |
Why?
|
| Cytomegalovirus | 1 | 2023 | 76 | 0.050 |
Why?
|
| Iron | 1 | 2023 | 168 | 0.050 |
Why?
|
| Allografts | 1 | 2023 | 181 | 0.050 |
Why?
|
| Anastomotic Leak | 1 | 2023 | 103 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2020 | 2863 | 0.050 |
Why?
|
| Esophagectomy | 1 | 2022 | 92 | 0.050 |
Why?
|
| Risk Factors | 2 | 2024 | 5466 | 0.050 |
Why?
|
| Esophagoscopy | 1 | 2021 | 90 | 0.050 |
Why?
|
| Esophagus | 1 | 2021 | 106 | 0.050 |
Why?
|
| Autopsy | 1 | 2021 | 122 | 0.050 |
Why?
|
| In Situ Hybridization | 1 | 2021 | 313 | 0.050 |
Why?
|
| Ostomy | 1 | 2020 | 15 | 0.050 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2020 | 76 | 0.040 |
Why?
|
| Animals | 4 | 2023 | 27324 | 0.040 |
Why?
|
| Organic Chemicals | 1 | 2019 | 34 | 0.040 |
Why?
|
| Seasons | 1 | 2021 | 237 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2023 | 475 | 0.040 |
Why?
|
| Interleukin-16 | 1 | 2019 | 7 | 0.040 |
Why?
|
| Enterococcus faecalis | 1 | 2019 | 54 | 0.040 |
Why?
|
| Random Allocation | 1 | 2019 | 328 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2019 | 233 | 0.040 |
Why?
|
| Bismuth | 1 | 2018 | 8 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 69 | 0.040 |
Why?
|
| Salicylates | 1 | 2018 | 25 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 58 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 336 | 0.040 |
Why?
|
| Organoplatinum Compounds | 1 | 2018 | 97 | 0.040 |
Why?
|
| Reference Values | 1 | 2019 | 661 | 0.040 |
Why?
|
| Infant | 1 | 2024 | 3147 | 0.040 |
Why?
|
| Remission Induction | 1 | 2019 | 740 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2019 | 519 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2023 | 1067 | 0.040 |
Why?
|
| Organometallic Compounds | 1 | 2018 | 134 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2024 | 3717 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 1710 | 0.030 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2016 | 21 | 0.030 |
Why?
|
| Hydralazine | 1 | 2016 | 19 | 0.030 |
Why?
|
| Fumarates | 1 | 2016 | 19 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2020 | 699 | 0.030 |
Why?
|
| Losartan | 1 | 2016 | 30 | 0.030 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2018 | 176 | 0.030 |
Why?
|
| Amides | 1 | 2016 | 53 | 0.030 |
Why?
|
| Intestines | 1 | 2019 | 416 | 0.030 |
Why?
|
| Survival Rate | 1 | 2020 | 1889 | 0.030 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2016 | 46 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 2752 | 0.030 |
Why?
|
| Angiotensin II | 1 | 2016 | 93 | 0.030 |
Why?
|
| Chicago | 1 | 2020 | 1423 | 0.030 |
Why?
|
| Th17 Cells | 1 | 2016 | 84 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 850 | 0.030 |
Why?
|
| Smoking | 1 | 2019 | 620 | 0.030 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 309 | 0.030 |
Why?
|
| Endosonography | 1 | 2016 | 98 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 1214 | 0.030 |
Why?
|
| Genotype | 1 | 2020 | 1848 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 975 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2018 | 500 | 0.030 |
Why?
|
| Lung | 1 | 2021 | 1258 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1715 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 866 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 481 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 2014 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2019 | 1990 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 786 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 2291 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 1265 | 0.030 |
Why?
|
| Crohn Disease | 1 | 2020 | 758 | 0.030 |
Why?
|
| Biomarkers | 1 | 2019 | 1755 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 2001 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 1574 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2016 | 688 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 2553 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 3211 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 3657 | 0.020 |
Why?
|
| Apoptosis | 1 | 2016 | 1717 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2018 | 4273 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 2412 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2019 | 3374 | 0.020 |
Why?
|
| United States | 1 | 2019 | 6957 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 1992 | 2347 | 0.010 |
Why?
|